Sanofi/Regeneron’s Dupixent, the Darling of Atopic Dermatitis
According to the latest update from Spherix Global Insights, dermatologists are highly satisfied with Dupixent, but a robust pipeline promises to bring competition. How much of a competitive advantage will its first-to-market status be? Download Report Overview EXTON, Pa., May 3, 2018 /PRNewswire/ — Since the March 2017 launch, growth and adoption of Dupixent has […]
Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis Management
A recent study published by Spherix Global Insights reveals that the newest psoriasis entrant, Tremfya, has made substantial gains in penetrating first-line biologic therapy for psoriasis. Download Report Overview EXTON, Pa., March 8, 2018 /PRNewswire/ — The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics […]
Growth of Sanofi-Regeneron’s Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer’s Eucrisa Carves a Niche with Younger Patients
While dermatologists satisfaction with Dupixent is exceptionally high and nearly all consider it an advance over other treatment options, Q1 2018 marks the first quarter with no significant gains in the user base or average number of patients being treated, according to the latest quarterly update from Spherix Global Insights Download Report Overview EXTON, Pa., […]
JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus
Recent milestones include Pfizer’s Xeljanz approval for PsA in December, the pending review of Xeljanz in UC expected in mid-2018, and this week’s announcement by AbbVie that its JAK1 has been granted Breakthrough Therapy Designation by the FDA for atopic dermatitis. EXTON, Pa., January 10, 2018 /PRNewswire/ — On-going, independent research conducted by Spherix Global […]
US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings. Download Report Overview EXTON, Pa., Nov. 30, 2017 /PRNewswire/ — The most recent release of […]
Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis
According to Spherix Global Insights’ latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is largely comparable to that of Taltz’s at a similar post-launch timeframe. Download Report Overview EXTON, Pa., Nov. 29, 2017 /PRNewswire/ — At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, […]
Janssen’s Stelara and Novartis’ Cosentyx Take the Cake When Psoriasis Patients Switch between Biologic/Otezla Agents, According To a Recent Audit of Nearly 1,000 Recently Switched Psoriasis Patients Conducted by Spherix Global Insights
Over one in five psoriasis patients are reported to switch between biologics or Celgene’s Otezla to a different brand within a given year Download Report Overview EXTON, Pa., October 31, 2017 /PRNewswire/ — Spherix Global Insights announces the release of RealWorld Dynamix™: Biologic and Otezla Switching in Psoriasis, a project undertaken in collaboration with 201 […]
Early Launch Metrics for Janssen’s Tremfya May Lag Those of Lilly’s Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin
According to Spherix Global Insight’s latest quarterly release of RealTime Dynamix™: Psoriasis, dermatologists are feeling increasingly overwhelmed with the sheer number of new biologic entrants recently approved in the US. Download Report Overview EXTON, Pa., Sept. 14, 2017 /PRNewswire/ — At just over one-month post launch, more dermatologists were aware of Taltz’s approval compared to […]
Uptake of Sanofi/Regeneron’s Dupixent for Atopic Dermatitis Strong, but Sales Representative Contact Rates Leave Something to be Desired
At roughly four months post-launch, the Dupixent patient and user base has experienced substantial growth, though nearly one-third of US dermatologists have yet to see a sales representative according to recent report from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 21, 2017 /PRNewswire/ — According to the Q3 update of RealTime Dynamix™: Atopic […]
RealTime Dynamix™: Atopic Dermatitis US Q3
Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash. Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. […]